1 Mutation in CDC42 gene set as a response biomarker

2 for immune checkpoint inhibitor therapy

3 Kun Wang^{1,2,3†}, Yingying Zhang^{1,2,3†}, Zhaoming Su³, Bei Wang³, Yuanyang Zhou³, Xiaochu Tong³,

```
4 Chengying Xie<sup>3,4</sup>, Xiaomin Luo<sup>3</sup>, Sulin Zhang<sup>3*</sup>, Mingyue Zheng<sup>1,2,3*</sup>
```

5 ¹ School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of

- 7 ² The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine,
- 8 University of Science and Technology of China, Hefei, 230001, China
- 9 ³ Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia
- 10 Medica, Chinese Academy of Sciences; 555 Zuchongzhi Road, Shanghai 201203, China
- ⁴ Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road,
- 12 Shanghai, 201210, China
- 13
- 14 [†] These authors contributed equally to this work.
- 15
- 16 Corresponding author. M. Zheng, School of Life Sciences, Division of Life Sciences and Medicine, University of
 17 Science and Technology of China, Hefei, 230026, China. E-mail: myzheng@simm.ac.cn; S. Zhang, Drug
 18 Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
 19 Chinese Academy of Sciences; 555 Zuchongzhi Road, Shanghai 201203, China. E-mail addresses:
 20 slzhang@simm.ac.cn.
- 21

22 Abstract

23 Background

⁶ China, Hefei 230026, China

- 24 Immunotherapy has proven notably effective in treating tumors across diverse patient populations. However, some
- 25 patients do not respond to immune checkpoint inhibitors (ICIs). Thus, there is a need for reliable biomarkers that
- 26 can predict clinical responses to ICI treatment accurately.

27 Methods

- 28 Our focus is on CDC42, a protein that stimulates multiple signaling pathways, promoting tumor growth. We
- 29 hypothesize that its defective function may indicate a patient's response to ICI therapy. We consider CDC42, along
- 30 with its downstream binding and effector proteins, as a gene set. This is because their mutation could result in
- 31 defective CDC42 function. We investigated the mutations in the CDC42 gene set as a potential biomarker for
- 32 clinical benefits from ICI treatment. We also examined whether the combined use of a CDC42 inhibitor and ICI
- 33 could enhance the efficacy of ICI.
- 34 **Results**
- 35 The presence of mutations in the CDC42 gene set correlated with improved overall survival (OS: p = 2.9E-4) and
- 36 progression-free survival (PFS: p = 2.92E-6). Furthermore, our analysis of immune response landscapes among
- 37 different CDC42 gene set statuses supports its potential as a biomarker for ICI therapy. Animal experiments also
- 38 revealed that combining the CDC42 inhibitor (ML141) with anti-PD-1 blockade can synergistically reduce tumor

39 growth.

40 Conclusions

- 41 Our study suggests that the CDC42 gene set could serve as a novel biomarker for the clinical response to ICI
- 42 treatment. This finding also provides insight into the potential of combining ICI and CDC42 inhibitor use.

43

44 Key words: Immunotherapy, Biomarker, CDC42, Clinical response, Pan-cancer

45

46 Background

47	Immune inhibitor therapy, such as anti-programmed cell death (ligand) 1 [PD-(L)1] and anti-cytotoxic T
48	lymphocyte antigen 4 (CTLA-4) drugs, has been successful in cancer therapy and improving long-term survival for
49	patients. However, the effectiveness of immune checkpoint inhibitor (ICI) drugs can vary greatly among different
50	patients due to tumor heterogeneity. While these drugs have shown positive effects in some patients, 60%-80% of
51	patients do not respond clinically to them[1]. Therefore, it is important to identify predictive biomarkers that can
52	indicate patients' clinical benefit[2].
53	
54	CDC42 is a type of ras homologous (rho) GTPase. Previous studies have reported that CDC42 simulates tumor
55	genesis, progression, invasion and metastatic[3]. In a previous study by Kalim et al., it was reported that inhibiting
56	CDC42 activity in regulatory T cells (Tregs) can enhance anti-tumor immunity[4]. While Kalim et al. report that
57	the immuno-effect of the CD42 inhibitor outweighs any tumor cell-intrinsic effect[4], it has also been reported
58	that a low level CDC42 in the serum can predict the clinical response to ICI in patients with advanced
59	hepatocellular carcinoma (HCC) [5] and advanced cervical cancer[6]. Therefore, it is valuable to explore the
60	defective function of CDC42 signaling in tumors beyond Tregs and whether it can raise the probability of a
61	response to ICI. If the defective function of CDC42 signaling is a biomarker for ICI therapy, it could provide
62	further insight into the combined use of ICI and CDC42 inhibitor.
63	

The function of CDC42 in control cell growth and polarity not only depends on itself but also on its binding protein and effector protein. Therefore, we consider CDC42, its binding protein, and effector protein as a gene set and investigate their potential as a biomarker for indicating the clinical benefit of ICI therapy, i.e., explore the defectiveness of CDC42 function's biomarker role indirectly. We examine whether there is a significant difference in overall survival (OS) and progression-free survival (PFS) among patients with different CDC42 gene set statuses. And we do bootstrap based on collected ICI therapy datasets. Using the ICI therapy datasets and their

70	bootstrap samples, we assess whether the CDC42 gene set status can differentiate the clinical benefit of ICI
71	treatment in patients. To further explain the predictive performance of the CDC42 gene set status, we examine the
72	intrinsic and extrinsic immune response landscapes among its status. Additionally, we investigate whether the
73	CDC42 gene set status significantly differentiates signature levels reported to influence the efficacy of ICI therapy,
74	such as the level of CD8 T cell infiltration.
75	
76	Furthermore, to validate whether defective CDC42 function can serve as a biomarker for ICI, we investigated
77	whether ML141 could increase the survival time of mice. We selected mice with 4T1 breast carcinoma, which has
78	been shown to be highly resistant to anti-PD-1 or anti-CTLA-4 therapy for the experiment[7]. ML141 is a
79	selective and non-competitive inhibitor of CDC42[8], which was utilized to simulate the defective function of
80	CDC42. Our study also aims to demonstrate the potential of CDC42 inhibitors in improving the anti-tumor effects
81	of ICI, particularly in cases where tumors exhibit resistance to ICI therapy. Overall, our study explores the role of
82	CDC42 gene set status as a biomarker for ICI therapy and seeks evidence to support the use of a CDC42 inhibitor
83	to enhance the efficacy of the ICI inhibitors.

84

85 Methods

86 Materials

We collected nine whole exome sequencing (WES) data for biomarker discovery. The Miao2019 cohort consists of renal clear cell carcinoma patients treated with anti-PD-1 drugs[9]. The Hugo and Riaz cohorts comprise melanoma patients treated with anti-PD-1 drugs [10, 11]. The Miao2018 cohort consists of pan-cancer patients treated with either 1) anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) drugs, 2) anti-PD-1 drugs, or 3) a combination of both anti-CTLA-4 and anti-PD-1 drugs [12]. The Rizvi cohort comprises non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 drugs[13]. The Snyder and Van Allen cohorts consist of

93	melanoma patients treated with anti-CTLA-4 drugs [14, 15]. The Hellmann cohort comprises non-small cell lung
94	cancer patients treated with both anti-CTLA-4 and anti-PD-1 drugs[16]. The Liu cohort comprises melanoma
95	patients treated with anti-PD-1 drugs[17](see supplementary material Table S1). We downloaded eight WES
96	datasets and corresponding clinical information from the cBioPortal database (https://www.cbioportal.org). The
97	Riaz cohort was obtained from the original literature[12].
98	
99	The collected data pertains to the drug response of cancer patients undergoing ICI therapy. In order to combine
100	this data from multiple sources, we utilized the processing method described by Zhang et al[18]. Initially, we
101	excluded three tumor types with a sample size of less than 10. We also removed 33 samples that had a
102	non-evaluable response (NE), 7 samples that were not profiled and 7 samples classified as "OTHER
103	CONCURRENT THERAPY". Furthermore, we eliminated 151 duplicate samples in the Miao2018 cohort. This
104	cohort had 27 overlapping samples with the Rizvi cohort, 37 with the Snyder cohort, and 87 with the Van Allen
105	cohort.

106

Table 1 summarizes the characteristics of the filtered data. The ICI therapy dataset includes five tumor types:
Melanoma (n=422), Non-Small Cell Lung Cancer (128), Renal Cell Carcinoma (35), Bladder Cancer (27) and
Head and Neck Cancer (10). The ICI therapy dataset includes the following types of drug treatment: anti-PD-1
(306), anti-CTLA-4 (174) and anti-CTLA-4 + anti-PD-1 (142). The proportion of CDC42 gene set mutation in the
ICI therapy dataset is 18%.

112

Furthermore, we collected data from 32 types of solid cancer data from The Cancer Genome Atlas (TCGA) to conduct further analysis on the CDC42 gene set status as a biomarker. This data includes WES data, RNA-seq data, and patients' overall survival time. The WES and RNA-seq data were obtained using TCGAbiolinks[19], and

- the survival time data were collected from Liu et al[20]. Additionally, we obtained Cibersort immune infiltration
- 117 values and TCR Shannon for each TCGA cancer sample from Thorsson et al[21].
- 118
- **Table 1.** Characteristics of the ICI therapy dataset.

Characteristic	Num (Portion)			
Gender				
Male	334 (54%)			
Female	223 (36%)			
NA	65 (10%)			
Age				
<65	193 (31%)			
>=65	140 (23%)			
NA	289 (46%)			
Cancer type				
Melanoma	422 (68%)			
Non-Small Cell Lung Cancer	128 (20%)			
Renal Cell Carcinoma	35 (6%)			
Bladder Cancer	27 (4%)			
Head and Neck Cancer	10 (2%)			
Drug target				
anti-PD-1	306 (49%)			
anti-CTLA-4	174 (28%)			

anti-CTLA-4 + anti-PD-1	142 (23%)	
Treatment best response		
PR	136 (22%)	
CR	40 (6%)	
PD	259 (42%)	
SD	132 (21%)	
NA	55 (9%)	
Durable clinical benefit		
Benefit	240 (39%)	
Nonbenefit	304 (49%)	
ΝΑ	78 (12%)	
CDC42 gene set status		
Mutant	113 (18%)	
Wild type	509 (82%)	
Overall patients	622	

120 PR: partial response. CR: complete response. PD: progressive disease. SD: stable disease. NA: not available.

121

122 CDC42 gene set mutation definition

In this study, we defined the CDC42 gene set as a set of genes that includes CDC42, CDC42 binding protein
kinase alpha (CDC42BPA), CDC42 binding protein kinase beta (CDC42BPB), CDC42BPG CDC42 binding
protein kinase gamma (CDC42BPG), CDC42 effector protein 1 (CDC42EP1), CDC42 effector protein 2
(CDC42EP2), CDC42 effector protein 3 (CDC42EP3), CDC42 effector protein 4 (CDC42EP4), CDC42 effector
protein 5 (CDC42EP5), CDC42 small effector 1 (CDC42SE1), CDC42 small effector 2 (CDC42SE2). These

128	genes are involved in CDC42 function, and their mutation may affect CDC42's signal. If any gene in this gene set
129	undergoes a non-synonymous mutation, the CDC42 gene set status is defined as mutated, which means the

130 defective function of CDC42 to some extent.

131

132 Clinical endpoint analysis

133 The objective response rate (ORR) was defined as the proportion of patients who received ICI therapy and

- 134 achieved a complete response (CR) or partial response (PR)[22]. Durable clinical benefit (DCB) was defined as a
- 135 CR, PR, or stable diseases (SD) that lasted for more than 6 months[23].

136

137 Immune cell fraction analysis

138 We obtained the leukocyte fraction from Thorsson et al[21]. The lymphocyte fractions were aggregated by using

139 the cibersort estimate, including B cells naïve, B cells memory, T cells CD4 naïve, T cells CD4 memory resting, T

- 140 cells CD4 memory activated, T cells follicular helper, Tregs, T cells gamma delta, T cells CD8, NK cells resting,
- 141 NK cells activated, and Plasma cells[21]. The molecular estimate for tumor-infiltrating lymphocyte (TIL) fraction
- 142 was obtained by multiplying the aggregated lymphocyte fraction from the cibersort estimate with the leukocyte
- fraction obtained from Thorsson et al. The estimate for TIL fraction images was obtained from Saltz et al[24].

144

145 Immune signatures analysis

We obtained 29 immune signatures from He et al[25] and performed single-sample gene set enrichment analysis(ssGSEA) using the "GSVA" R package[26] based on these signatures.

148

149 **GSEA analysis**

150 We used TCGA RNA-seq data and the DESeq2 package[27] to identify differentially expressed genes.

151	Subsequently, we	conducted GSEA a	nalysis on the	e Kyoto Encyc	clopedia of C	Genes and Ge	enomes (KEGG) pa	thway
-----	------------------	------------------	----------------	---------------	---------------	--------------	------------------	-------

- using the clusterProfiler package[28].
- 153

154 **Estimation of cytolytic activity**

155 We estimated cytolytic activity (CYT) based on the method described by Rooney et al[29]. This involves

156 calculating the geometric mean of granzyme A (GZMA) and perforin 1 (PRF1) expression.

157

158 Mutation and neoantigens analysis

For this study, we assessed tumor mutational burden (TMB) using the number of non-synonymous mutations. The
data for nonsilent mutation, silent mutation, single nucleotide variation (SNV) neoantigens and indel neoantigens
were obtained from Thorsson et al[21].

162

163 **Statistical analysis**

164 We used the two-sided Fisher's exact test to explore the difference between CDC42 gene set status and clinical 165 benefit. To further assess the potential of CDC42 gene set as a biomarker for predicting the clinical benefits of ICI, 166 we employed bootstrapping to generate 1000 bootstrap samples for both CDC42 gene set mutation and wild type 167 patients. This allowed us to obtain empirical distributions for ORR and DCB[30]. Subsequently, we then 168 compared the 95% confidence intervals of ORR and DCB based on the CDC42 gene set status. The two-sided 169 Wilcoxon rank sum test was used to compare the TMB and neoantigen load (NAL) of ICI therapy data. We also 170 used the two-sided Wilcoxon rank sum test to compare TCGA gene expression levels, mutation rate, neoantigens, 171 cell fraction, immune signatures, TCR Shannon and CYT between the CDC42 gene set mutation group and the 172 CDC42 gene set wild type group. Additionally, we plotted the KM curve of PFS and OS using the logrank test based on CDC42 gene set status, which used the χ^2 test statistic to calculate P values[31]. Fisher's exact test was 173

implemented using the python package scipy[32]. The logrank test, Cox Proportional-Hazards analysis, and
Wilcoxon rank sum test were implemented using the survminer package and ggsignif package in R version 4.2.3
(https://www.r-project.org).

177

178 Animal experiment

179 All procedures performed on animals were conducted in accordance with the Institutional Animal Care and Use 180 Committee at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (IACUC Issue NO. 181 2023-10-ZMY-03). For the pharmacodynamics experiment, BALB/c mice (6-8 weeks old) were purchased and inoculated subcutaneously with 1×10^{6} 4T1 tumor cells into the right side of the mice's axilla. The animals were 182 183 divided into four groups irregularly once the tumor volume reached approximately to 100 mm³. ML141 184 (#HY-12755, MedChemExpress) was administered in a solution containing PEG300, dimethyl sulfoxide, and PBS 185 [40/5/55 (v/v/v)]. The mice were then treated intraperitoneally with or without ML141 (30 mg/kg once a day) 186 and/or 150 µg/mouse of anti-PD-1 antibody (#-BE0273, Bio X Cell) every other day for one injection. Tumor 187 volumes were calculated using the formula: $V = (length \times width^2)/2$. Body weights and tumor volumes of the mice 188 were measured daily. The tumor growth inhibition (TGI) value was calculated using the formula: TGI= 189 [1-Relative Tumor Volume (Treatment)/Relative Tumor Volume (Vehicle)] ×100%.

190

Flow cytometry analysis

192 The tumor tissues were firstly digested into single cells using a digestion solution containing 0.001% 193 hyaluronidase, 0.1% collagenase, 0.002% DNase, 120 μM MgCl2, and 120 μM CaCl2 in RPMI 1640 medium. 194 Subsequently, red blood cells were lysed using ammonium chloride for 3 minutes and then the cell samples were 195 stained with Fixable Viability Stain 700 (#564997, BD). The Fc receptors were blocked with TruStain FcXTM 196 (anti-mouse CD16/32) antibody (#101320, Biolegend) and stained with the following antibodies: APC-Cy7 rat

197 anti-mouse CD45 (#557659, BD), FITC CD3 monoclonal antibody (17A2) (#11-0032-82, Invitrogen), and

- 198 Brilliant Violet 421 anti-mouse CD8a antibody (#100738, Biolegend). The stained cells were analyzed using the
- 199 Agilent Novocyte 3000 instrument, and all data were analyzed with FlowJo software.
- 200

201 **Results**

202 Mutation in CDC42 gene set was associated with improved clinical outcomes for ICI therapy.

- As shown in Fig.1 a, the ORR of patients in the CDC42 gene set mutation group (ORR = 53%, 53/100) was
- significantly higher (p = 6.59E-7) compared to the CDC42 gene set wild type group (ORR = 26.34%, 123/467).
- Additionally, the DCB of patients in the CDC42 gene set mutation group (DCB = 64.21%, 61/95) was also significantly higher (p = 2.12E-5) than the wild type group (DCB = 39.87%, 179/449). Moreover, CDC42 gene set mutation patients had significantly longer overall survival time (p = 2.9E-4, HR = 0.52, 95%CI = 0.36-0.75) and
- progression-free survival time (p = 2.92E-6, HR = 0.46, 95%CI = 0.33-0.64) compared to the CDC42 gene set
- wild type group.

210

211 We divided the collected ICI therapy dataset into two groups: CDC42 gene set mutation group and CDC42 gene 212 set wild type group. For each patient group, we sampled 1000 times to further explore ORR's difference in 213 different CDC42 gene set statuses. The same operation was also performed on DCB. As shown in Fig. 1e, the 214 mean values distribution of ORR was significantly different between the two patient groups (p < 2.22E-16). The 215 95% confidence interval (CI) was 0.22-0.30, with a standard deviation (STD) was 0.02 in CDC42 gene set wild 216 type group. In CDC42 gene set mutation group, the 95% CI was 0.43-0.63, and the STD was 0.05. Similarly, in 217 Fig. 1f, the mean values distribution of DCB was significantly different between the two patient groups (p < p218 2.22E-16). The 95%CI was 0.35-0.45, with a STD of 0.024 in CDC42 gene set wild type group. In CDC42 gene 219 set mutation group, the 95% CI was 0.54-0.74, and the STD was 0.051. Based on these results, it can be inferred

- that patients with CDC42 gene set mutations are more likely to have clinical benefits from receiving ICI treatment.
- 221 Overall, the results in Fig. 1 suggest that the CDC42 gene set mutation could serve as a biomarker for the clinical
- response of ICI treatment.
- 223



225	Fig.1. Analysis of CDC42 gene set mutation as a biomarker for ICI therapy. a, The differences in ORR between CDC42 gene set
226	mutation and CDC42 gene set wild type groups. b, The differences in DCB between CDC42 gene set mutation and CDC42 gene set
227	wild type groups. c, The KM curve of OS based on the CDC42 gene set status. d, The KM curve of PFS based on the CDC42 gene
228	set status. e, The distribution of mean values of ORR based on bootstrap samples. f, The distribution of mean values of DCB based
229	bootstrap samples. ORR, objective response ratio; DCB, durable clinical benefit; KM, Kaplan-Meier; OS, overall survival; PFS,
230	progression-free survival.
231	
232	Assessment of intrinsic immune response landscapes in CDC42 gene set wild type and
233	mutation tumors
234	We initially examined the relationship between CDC42 gene set status and immunogenicity in the ICI therapy
235	cohort. As shown in Fig. 1a and Fig. 1b, the levels of TMB and NAL in the CDC42 gene set mutation group were
236	significantly higher than those in the CDC42 gene set wild type group (TMB: $p < 2.22E-16$, NAL: $p = 8.1E-14$).
237	These findings indicate a strong association between CDC42 gene set mutations and increased immunogenicity, as
238	well as a higher likelihood of positive responses to ICI therapy. We also explored the relationship between CDC42
239	gene set status and immunogenicity in the TCGA cohort. Compared to CDC42 gene set wild type tumors, both the
240	nonsilent mutation rate and the silent mutation rate were significantly higher than in CDC42 gene set mutation
241	tumors (p < 2.22E-16, Fig.2c, d). Additionally, both SNV neoantigens and indel neoantigens were significantly
242	more abundant in in CDC42 gene set mutation tumors compared to CDC42 gene set wild type tumors (p $<$
243	2.22E-16, Fig.2e, f). These results in the TCGA cohort further support the notion that the CDC42 gene set mutations
244	are associated with enhanced tumor immunogenicity.
245	

246 Then, we investigated the relationship between CDC42 gene set status and the expression of immune-related 247 molecules, including two class MHC molecules, immune checkpoint, and co-stimulators. We found that immune

248	checkpoint genes PDCD1, CD274 and CTLA-4 were upregulated in the CDC42 gene set mutation group. as
249	shown in Fig 2h-j. Additionally, we observed significantly higher expression of MHC1, MHC2, other immune
250	checkpoints (ICPs), and co-stimulators in CDC42 gene set mutation tumors compared to CDC42 gene set wild
251	type, as shown in Fig. 2g. Previous studies have suggested that higher expression of immune checkpoint-related
252	genes is indicative of a better response to ICIs therapy[33, 34]. MHC1 plays a crucial role in presenting antigens
253	to CD8 T cells, and its down-regulation is associated with resistance to ICIs[35]. Moreover, positive expression of
254	MHC2 correlates with a response to ICIs therapy[36]. Co-stimulators can promote T cell activation and survival,
255	and activation of co-stimulatory pathways enhances checkpoint inhibition[37, 38]. In summary, these results

demonstrate that CDC42 gene set mutation is a strong predictive biomarker for ICI therapy response.



260 nonsilent mutation rate, d. silent mutation rate, e. SNV neoantigens, f. indel neoantigens, g. expression of MHC and other ICP

261 molecules and costimulators, h. expression of PDCD1, i. expression of CD274, j. expression of CTLA-4 between CDC42 gene set

wild type and CDC42 gene set mutation groups in the TCGA cohort. TMB, tumor mutation load; ICI, immune checkpoint inhibitor;

263 NAL, neoantigen load; SNV, single nucleotide variant; ICP, immune checkpoint. *P < 0.05, **P < 0.01, ****P < 0.001, ****P <

264 0.0001

265

257

258

259

266 Assessment extrinsic immune response landscapes in CDC42 gene set wild type and mutation

267 tumors

268 The different situations of immune cell infiltration result in different clinical outcomes of ICI therapy[39]. 269 Therefore, we investigated the difference in tumor microenvironment (TME) between CDC42 gene set wild type 270 and mutation tumors. This included analyzing immune cell score, signatures representing their function, and 271 differential gene expression related to immune cell and ICI therapy efficiency. 272 273 As shown in Fig. 3a and 3b, the leukocyte fraction and lymphocyte fraction in CDC42 gene set mutation tumors 274 were significantly higher than those in CDC42 wild type gene set tumors (leukocyte fraction, p = 5.7E-06; 275 lymphocyte fraction, p = 6.3E-06). As TIL is crucial for killing tumors[40], TIL fractions estimated at both 276 molecular and image levels were compared. Fig. 3c shows that TIL fractions (molecular estimate) in CDC42 gene 277 set mutation tumors are significantly higher than those in CDC42 gene set wild type tumors (p = 9.5E-3). Fig. 3d 278 shows that TIL fractions (images estimate) in CDC42 gene set mutation tumors are significantly higher than in 279 those in CDC42 gene set wild type tumors (p = 3E-06). These results indicate that CDC42 gene set mutation 280 tumors are more likely to be recognized and killed by immune cells than CDC42 gene set wild type tumors. 281 282 Cibersort scores based on the TCGA cohort were also compared between CDC42 gene set wild type and mutation 283 tumors. As shown in Fig. 3e, the percentages of immune cell types were compared in detail. We found significant 284 differences in most of the immune cell scores between CDC42 gene set wild type and mutation tumors. For 285 example, the CD8 T cell and macrophage M1 cell scores in the CDC42 gene set mutation type were significantly 286 higher than that in the CDC42 gene set wild type tumors. These findings are consistent with previous reports that 287 CD8 T cell are key determinants of response to ICI, and macrophage M1 cells are related to T cell stimulation and 288 ICI therapy[34, 41]. Fig. 3f shows ssGSEA results based on 29 immune signatures. We found that CD8 T cell and 289 checkpoint signatures in CDC42 gene set mutation type tumors were significantly higher than those in CDC42

290 gene set wild type tumors. These results are also consistent with previous reports that CD8 T cells are key

291 determinants of response to ICI and higher expression of immune checkpoint-related genes is more likely to

benefit clinically from ICIs treatment[33]. Fig. 4a further shows that immune signatures were significantly

enriched in CDC42 gene set mutation tumors compared to CDC42 gene set wild type tumors.



294

Fig.3. Analysis of extrinsic immune response landscapes of CDC42 gene set wild type and CDC42 gene set mutation tumors in

296	the TCGA cohort. Comparison of a. leukocyte fraction, b. lymphocyte fraction, c. TIL fraction based on molecular estimates, d. TIL
297	fraction based on images estimates, e. immune cell infiltration, f. 29 immune signatures estimated through the ssGSEA method
298	between CDC42 gene set wild type and CDC42 gene set mutation tumors. * $P < 0.05$, ** $P < 0.01$, **** $P < 0.001$, **** $P < 0.001$

299

300 We further conducted GSEA analysis, as well as expression analysis of chemokines and chemokines receptors, 301 interleukins and interleukins receptors, TCR, and cytolytic activity score based on CDC42 gene set status. In Fig. 302 4b, we observed enrichment of base excision repair, homologous recombination, mismatch repair pathway 303 enriched in CDC42 gene set mutation tumors, while fatty acid degradation and Ras signaling pathway were 304 enriched in CDC42 gene set wild type tumors. These results align well with previous reports. For example, Jiang 305 et al reported that DDR pathways are associated with the response to ICIs treatment[42]. Ward et al reported that 306 activation of the Ras signaling pathway leads to an immunosuppressive tumor microenvironment, hindering T 307 cells activation and infiltration, thus affecting the therapeutic efficacy of ICI[43]. Li et al reported that increased 308 lipid content is correlated with a favorable ICI response[44], suggesting that higher lipid accumulation may 309 indicate a higher likelihood of a positive response to ICI therapy. In Fig. 4c, we found a higher TCR Shannon 310 score in CDC42 gene set mutation tumors compared to that in CDC42 gene set wild tumors (p = 2.9E-3). Higher 311 TCR diversity may indicate that T cells can recognize more neoantigens, and studies have shown that patients 312 with higher TCR diversity scores have more favorable clinical responses to ICI treatment[45]. The cytolytic 313 activity score in CDC42 gene set mutation patients was significantly higher than in CDC42 gene set wild type 314 patients (Fig.4d, p <2.22E-16). CYT is upregulated during T cell activation[46], indicating that upregulated CYT 315 leads to more effective tumor killing. As shown in Fig. 5e, most chemokines in CDC42 gene set mutation patients 316 were significantly higher than in CDC42 gene set wild type patients. Previous studies have reported that CXCL9, 317 CXCL10 and CXCL11 can enhance T cell infiltration, thereby improving the therapeutic efficacy of ICI

318	interventions[47-49]. The expression of CXCL13 can generate effector T cells and is closely associated with the
319	response to ICIs treatment[50]. There were also significant differences in interleukins and interleukins receptors
320	expression between CDC42 gene set statuses, consistent with previous study reports. Pegilodecakin (PEGylated
321	recombinant IL \square 10) induces the proliferation of CD8 T cells both within the tumor microenvironment and in the
322	systemic circulation, while also activating CD8 T cells within TME[51]. IL-21 functions as a robust survival
323	factor for both natural killer (NK) and T cells, while also inhibiting the differentiation of Tregs[52]. Therefore, the
324	significantly high expression of IL 10 and IL-21 in CDC42 gene set mutation patients may indicate the presence
325	of more CD8 T cells in TME and a higher probability of a positive response to ICI therapy compared to patients
326	with CDC42 gene set wild type status. Moreover, the association of IL-33 with the establishment of a tumorigenic
327	niche has been reported[53], suggesting that its elevated expression in CDC42 wild type patients might imply a
328	reduced likelihood of responding to ICI therapy. Overall, through the above analyses, we observed enhanced
329	immunity and a greater probability response to ICI in CDC42 gene set mutation patients compared to CDC42
330	gene set wild type patients.



331

Fig.4. Analysis of gene expression related to immune cell between CDC42 gene set wild type and CDC42 gene set mutation tumors in the TCGA cohort. a, Volcano plots showing the analysis of 29 immune signatures estimated by the ssGSEA method for CDC42 gene set wild type and CDC42 gene set mutation tumors. b, GSEA analysis results based on CDC42 gene set status, with gene sets having an FDR (Benjamini-Hochberg method) lower than 0.25 considered significantly enriched. c, Comparison of the TCR Shannon score between CDC42 gene set wild type and CDC42 gene set mutation tumors. d, Comparison of the cytolytic

activity score between CDC42 gene set wild type and CDC42 gene set mutation tumors. e, Comparison of the chemokines (and
receptors) and interleukins (and receptors) between CDC42 gene set wild type and CDC42 gene set mutation tumors. $*P < 0.05$, $**P$
< 0.01, ***P < 0.001, ****P < 0.0001.

340

341 Exploring the synergy of CDC42 inhibitor in combination with ICI to enhance 342 immunotherapy efficacy

343 We investigated the antitumor effect of combining a CDC42 inhibitor (ML141) with anti-PD-1 antibody. 344 Treatment with anti-PD-1 antibody alone demonstrated ordinary therapeutic capacity, with a TGI of 38% (Fig. 5a). 345 Treatment with ML141 alone resulted in a TGI of 63% (Fig. 5a). Notably, the combination of ML141 and 346 anti-PD-1 antibody significantly reduced tumor growth (TGI = 86%) and prolonged survival time compared to the 347 anti-PD-1 antibody alone group (Fig. 5a and 5b). This suggests that the combination therapy can effectively exert 348 potent antitumor immune activity. Furthermore, these treatments did not lead to weight loss in the mice (Fig. 5c), 349 indicating that this dosing regimen is safe. To determine the role of the immune response in the antitumor activity 350 of this dosage regimen, we analyzed the immune cells' infiltration in the TME using flow cytometry experiments. 351 The results showed that a combination of ML141 and an anti-PD-1 antibody significantly increased the frequency 352 of CD45+ lymphocytes, CD3+ T cells, and CD8+ cytotoxic T cells in the TME compared to the anti-PD-1 353 antibody alone (Fig. 5d-f, Fig. S1). Furthermore, the use of ML141 alone also raised the frequency of CD3+ T 354 cells and CD8+ cytotoxic T cells in the TME, aligning with earlier discoveries that the pharmacological inhibition 355 of CDC42 triggers antitumor immune activity[4]. Interestingly, the CDC42 inhibitor mimics the defective 356 function of CDC42 to a certain degree. As a result, our experiment confirms that the defective function of CDC42 357 is a biomarker for ICI therapy. Overall, these findings suggest that CDC42 inhibitor, used in conjunction with ICI, 358 synergistic therapeutic effect and has а can enhance the efficacy of immunotherapy.



Fig. 5 ML141 enhances Anti-PD-1 antibody induced tumor inhibition *in vivo*. **a**, Growth curves of tumors from the indicated groups (n = 8). **b**, Kaplan-Meier survival curves of mice in the indicated group (n = 8). **c**, Body weight change curves of mice in the indicated group. **d-f**, Impact of Anti-PD-1 antibody alone, ML141 alone, or a combination of both on the frequency of CD45⁺ lymphocytes, CD3⁺ T cells, and CD8⁺ T cells in TEM, assessed by flow cytometry. Error bars represent mean ± SEM; statistical analysis by Wilcoxon rank sum test (a) or logrank test (b) or two-tailed unpaired t-test (d-f). *, P < 0.05; **, P < 0.01; ns, no statistical difference, P > 0.05.

366

359

367 **Discussion**

368 CDC42 downstream signals are known to be involved in stimulating tumors, including tumorigenesis, progression,

369	invasion, and metastasis[3]. The purpose of this study is to investigate whether the defective function of CDC42
370	could be used as a biomarker for ICI therapy. We hypothesized that CDC42's function may not only depend on
371	CDC42 itself but also on its binding protein and effector protein. These genes are collectively referred to as the
372	CDC42 gene set. Mutations in the CDC42 gene set genes may result in the partial defectiveness of CDC42
373	function. By analyzing a dataset of patients undergoing ICI treatment, we observed that patients with CDC42 gene
374	set mutations had a higher rate of ORR and DCB. Additionally, these patients showed significantly longer OS and
375	PFS time compared to patients with wild type CDC42 gene set genes. Bootstrap samples further confirmed that
376	patients with CDC42 gene set mutations are more likely to respond to ICIs than patients with wild type CDC42
377	gene set genes. These analyses indicate that CDC42 gene set mutation can serve as a clinical biomarker for ICI
378	therapy. In animal experiments, employing CDC42 inhibitors to mimic the defective function of CDC42 resulting
379	in improved survival times in mice that were initially insensitive to anti-PD-1 treatment. This finding further
380	validates the utility of the defective function of CDC42 as a potential biomarker for ICI treatment to some extent.

381

382 We conducted a further analysis of the CDC42 gene set's status to better understand its role in indicating the 383 clinical response to ICI using the TCGA dataset. Our findings revealed that tumors with CDC42 gene set 384 mutations exhibited stronger immunogenicity, as evidenced by higher TMB and NAL. Additionally, we compared 385 the gene expression levels of MHC1, TCR Shannon, and CYT, and observed significantly higher expression levels 386 of these genes in patients with CDC42 gene set mutations. MHC1 plays a crucial role in presenting antigens to 387 CD8 T cells, and its down-regulation has been associated with resistance to ICI[35]. Moreover, elevated level of 388 TCR diversity and high expression of CYT indicate T cell activation and enhanced tumor cell killing efficiency. In 389 summary, these comparisons highlight a more active immune response in CDC42 gene set mutation patients, 390 characterized by stronger immunogenicity and the potential for more effective T cell activation and killing 391 through increased MHC1 antigen presentation and TCR diversity, as well as higher CYT expression.

392

393	In TME, leukocyte fraction, lymphocyte fraction, TIL fraction and CD8 T cell levels were substantially higher in
394	patients with CDC42 gene set mutations compared to those with CDC42 gene set wild type, indicating enhanced
395	immunity. The increased expression of chemokines, such as CXCL9, CXCL10 and CXCL11, in patients with
396	CDC42 gene set mutations can recruit more T cells into TME[47-49]. Additionally, higher expression of
397	interleukins, like IL-10 and IL-21, in CDC42 gene set mutation patients promotes the survival of T cells. These
398	findings suggest that CDC42 gene set mutation patients have a TME with increased infiltration of immune cell,
399	particularly CD8 T cells, which experience improved survival conditions. Studies have shown that CD8 T cells
400	play a critical role in eliminating tumors, and their presence within the tumor microenvironment is associated with
401	better clinical responses to ICI treatments[34]. Furthermore, elevated expression of ICPs has been linked to
402	positive responses to ICI treatments[33]. Therefore, the utilization of ICI therapies in patients with CDC42 gene
403	set mutations (who exhibit elevated expression of ICPs) may potentially restore the suppressed function of CD8 T
404	cells. In summary, the aforementioned analyses collectively highlight the significance of considering CDC42 gene
405	set mutations as a potential biomarker for predicting responses to ICI treatment.
406	
407	Some other biomarkers for ICI treatment, such as NOTCH4[54] and PAPPA2[55], do not indicate whether their
408	biomarker function come from the alternation of their function, and the potential for combining their inhibitors
409	with ICI was not examined. We hypothesize that the function of CDC42 may not only depend on itself but also its
410	downstream binding protein and effector function. Mutations in CDC42 gene set result in the defective function of
411	CDC42 and inhibition of tumor growth, which further releases immune suppression. Therefore, the functional
412	defectiveness in CDC42 may underlie its potential as a biomarker for clinical benefit from ICI therapy. The
413	significant difference between mutations in CDC42, its downstream binding proteins and effector proteins and the

414 clinical benefit of ICI partially confirms our hypothesis. Hence, we propose that the combined use of ICI and

415	CDC42 inhibitors could further enhance ICI's efficacy, and we conducted experiment exploration. Animal
416	experiment data demonstrated that the ML141 inhibitor indeed could further promote ICI's efficacy, further
417	confirming our hypothesis and providing valuable insights for further exploration in clinical settings.
418	

419 **Conclusion**

420 In conclusion, we have speculated that CDC42's function may depend not only on CDC42 itself but also its 421 binding proteins and effector proteins. We have also demonstrated that mutations in the CDC42 gene set could 422 serve as a novel biomarker for predicting the clinical response of ICI therapy. Furthermore, the analysis of the 423 TCGA dataset and the animal experiment further supports the role of this predictive biomarker. Additionally, this 424 study has provided insight into the potential synergistic effects of combining CDC42 inhibitors with ICIs to 425 enhance their efficacy, especially bringing hope to situations that failed to respond to anti-PD-1 treatment. Our 426 study introduces a novel approach to biomarker analysis, considering that changes in the function of a key gene 427 can result from mutations in downstream effector proteins as well. Analyzing gene sets collectively like this may 428 facilitate the discovery of new biomarkers and potential drug targets.

429

430 Abbreviations

431 CI: confidence interval; CR: complete response; CTLA-4: cytotoxic T lymphocyte-associated protein-4; CYT:

432 cytolytic activity; DCB: Durable clinical benefit; GSEA: gene set enrichment analysis; GZMA: granzyme A; HCC:

433 hepatocellular carcinoma; HR: hazard ratio; ICIs: immune checkpoint inhibitors; ICP: immune checkpoint; KEGG:

- 434 Kyoto Encyclopedia of Genes and Genomes; KM: Kaplan-Meier; NAL: neoantigen load; NE: non-evaluable; NR:
- 435 non-responder; ORR: objective response rate; OS: overall survival; PD: progressive disease; PD-1: Programmed
- 436 Death Receptor 1; PFS: progression-free survival; PFS: progression-free survival; PR: partial response; PRF1:
- 437 perforin 1; R: responder; Rho: ras homologous; SD: stable disease; SNV: single nucleotide variation; ssGSEA:

- 438 single-sample gene set enrichment analysis; STD: standard deviation; TCGA: The Cancer Genome Atlas; TCGA:
- 439 The Cancer Genome Atlas; TIL: tumor-infiltrating lymphocyte; TMB: tumor mutational burden; TME: tumor
- 440 microenvironment; Tregs: regulatory T cells; VEGF: vascular endothelial growth factor; WES: whole exome

441 sequencing

442

443 **Declarations**

444

445 **Ethics approval and consent to participate**

446 Not applicable.

447 **Consent for publication**

448 Not applicable.

449 Availability of data and materials

450 The datasets supporting the conclusions of this article are included within the article.

451 **Competing interests**

452 The authors declare that they have no competing interests.

453 **Funding**

- 454 We gratefully acknowledge financial support from National Natural Science Foundation of China (T2225002,
- 455 82273855 to M.Y.Z.), SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Program
- 456 (E2G805H), Shanghai Municipal Science and Technology Major Project, National Key Research and
- 457 Development Program of China (2022YFC3400504 to M.Y.Z.), the Youth Innovation Promotion Association CAS
- 458 (2023296 to S.L.Z.) and the Natural Science Foundation of Shanghai (22ZR1474300 to S.L.Z.).

459 Authors' contributions

460 M.Y.Z, S.L.Z, K.W and Y.Y. Zhang conceived of and designed the study. K.W and Y.Y. Zhang drafted the

	3
161	manuscript KW conducted the data analysis VV Thang and 7 MS performed the experiments CVX provided
401	manuscript. K. W conducted the data analysis. 1.1. Zhang and Z.W.S performed the experiments. C. I.A provided

- 462 administrative support. B.W, Y.Y. Zhou, X.C.T and X.M.L participated in the discussion. All authors read and
- 463 approved the final version of the manuscript and are accountable for all aspects of the work.

464 Acknowledgements

- 465 The authors would like to acknowledge their colleague, mentor, and friend, Dr. Hualiang Jiang (1965–2022), who
- took part in the work and in the preparation of the original manuscript.
- 467

468 **Reference**

- 469 1. Sharma, P., et al., *Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.* Cell, 2017.
- 470 **168**(4): p. 707-723.
- 471 2. *Cancer immunotherapy: the quest for better biomarkers.* Nat Med, 2022. **28**(12): p. 2437.
- 472 3. Xiao, X.H., et al., *Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and*
- 473 *MicroRNA as New Treatment Candidates.* Molecules, 2018. 23(4).
- 474 4. Kalim, K.W., et al., *Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell*
- 475 *immunity.* J Immunother Cancer, 2022. **10**(11).
- 476 5. Xu, J., et al., Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage
- 477 with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes. Clin Res
- 478 Hepatol Gastroenterol, 2023. **47**(7): p. 102149.
- 479 6. Guo, L., et al., Serum cell division cycle 42 reflects the treatment response and survival in patients
- 480 *with advanced cervical cancer who receive immune checkpoint inhibitor treatment.* Oncol Lett, 2023.
- 481 **26**(3): p. 414.
- 482 7. De Henau, O., et al., Overcoming resistance to checkpoint blockade therapy by targeting
 483 *Pl3Kgamma in myeloid cells*. Nature, 2016. **539**(7629): p. 443-447.

- 484 8. Chen, H.Y., et al., Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation
- 485 *capacity and tamoxifen sensitivity in basal-like breast cancer cells.* EMBO Mol Med, 2013. **5**(5): p.
- 486 723-36.
- 487 9. Miao, D., et al., *Genomic correlates of response to immune checkpoint therapies in clear cell renal*
- 488 *cell carcinoma.* Science, 2018. **359**(6377): p. 801-806.
- 489 10. Hugo, W., et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in
- 490 *Metastatic Melanoma.* Cell, 2016. **165**(1): p. 35-44.
- 491 11. Riaz, N., et al., Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell,
- 492 2017. **171**(4): p. 934-949 e16.
- 493 12. Miao, D., et al., *Genomic correlates of response to immune checkpoint blockade in*494 *microsatellite-stable solid tumors.* Nat Genet, 2018. **50**(9): p. 1271-1281.
- 495 13. Rizvi, N.A., et al., *Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade*
- 496 *in non-small cell lung cancer.* Science, 2015. **348**(6230): p. 124-8.
- 497 14. Snyder, A., et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med,
- 498 2014. **371**(23): p. 2189-2199.
- 499 15. Van Allen, E.M., et al., *Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.*500 Science, 2015. **350**(6257): p. 207-211.
- 501 16. Hellmann, M.D., et al., Genomic Features of Response to Combination Immunotherapy in Patients
- 502 with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 843-852 e4.
- 503 17. Liu, D., et al., *Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in* 504 *patients with metastatic melanoma.* Nat Med, 2019. **25**(12): p. 1916-1927.
- 505 18. Zhang, Z., et al., EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in
- 506 *multiple cancers.* BMC Med, 2021. **19**(1): p. 26.

- 507 19. Colaprico, A., et al., TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.
- 508 Nucleic Acids Res, 2016. **44**(8): p. e71.
- 509 20. Liu, J., et al., An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival
- 510 *Outcome Analytics.* Cell, 2018. **173**(2): p. 400-416 e11.
- 511 21. Thorsson, V., et al., *The Immune Landscape of Cancer.* Immunity, 2018. **48**(4): p. 812-830 e14.
- 512 22. Villaruz, L.C. and M.A. Socinski, The clinical viewpoint: definitions, limitations of RECIST, practical
- 513 considerations of measurement. Clin Cancer Res, 2013. **19**(10): p. 2629-36.
- 514 23. Rizvi, H., et al., Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and
- 515 Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer
- 516 Profiled With Targeted Next-Generation Sequencing. J Clin Oncol, 2018. **36**(7): p. 633-641.
- 517 24. Saltz, J., et al., Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes
- 518 Using Deep Learning on Pathology Images. Cell Rep, 2018. 23(1): p. 181-193 e7.
- 519 25. He, Y., et al., Classification of triple-negative breast cancers based on Immunogenomic profiling. J
- 520 Exp Clin Cancer Res, 2018. **37**(1): p. 327.
- 521 26. Hänzelmann, S., R. Castelo, and J. Guinney, *GSVA: gene set variation analysis for microarray and*
- 522 *RNA-seq data.* BMC bioinformatics, 2013. **14**: p. 1-15.
- 523 27. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for* 524 *RNA-seq data with DESeq2.* Genome Biol, 2014. **15**(12): p. 550.
- 525 28. Yu, G., et al., *clusterProfiler: an R package for comparing biological themes among gene clusters.*
- 526 OMICS, 2012. **16**(5): p. 284-7.
- 527 29. Rooney, M.S., et al., *Molecular and genetic properties of tumors associated with local immune* 528 *cytolytic activity.* Cell, 2015. **160**(1-2): p. 48-61.
- 529 30. Ruiz-Bañobre, J., et al., *Rethinking prognostic factors in locally advanced or metastatic urothelial*

- 530 *carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.* ESMO open,
- 531 2021. **6**(2): p. 100090.
- 532 31. Bland, J.M. and D.G. Altman, *The logrank test*. Bmj, 2004. **328**(7447): p. 1073.
- 533 32. Virtanen, P., et al., *SciPy 1.0: fundamental algorithms for scientific computing in Python.* Nat Methods,
- 534 2020. **17**(3): p. 261-272.
- 535 33. Hu, F.F., et al., *Expression profile of immune checkpoint genes and their roles in predicting* 536 *immunotherapy response*. Brief Bioinform, 2021. **22**(3).
- 537 34. Oba, T., et al., Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and
- 538 *activation of tumor-residing cDC1s.* Nat Commun, 2020. **11**(1): p. 5415.
- 539 35. Luo, N., et al., DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T
- 540 *lymphocyte responses in breast cancer.* Nat Commun, 2018. **9**(1): p. 248.
- 541 36. Johnson, D.B., et al., *Melanoma-specific MHC-II expression represents a tumour-autonomous* 542 *phenotype and predicts response to anti-PD-1/PD-L1 therapy.* Nat Commun, 2016. **7**: p. 10582.
- 543 37. Chen, L. and D.B. Flies, *Molecular mechanisms of T cell co-stimulation and co-inhibition.* Nature
- 544 Reviews Immunology, 2013. **13**(4): p. 227-242.
- Jeong, S. and S.H. Park, *Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy*. Immune Netw, 2020. 20(1): p. e3.
- 547 39. Liu, R., et al., Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic
- 548 *Efficacy: A Computational Retrospective Study.* Front Immunol, 2021. **12**: p. 685370.
- 549 40. Li, B., Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
- 550 Front Immunol, 2022. **13**: p. 973881.
- 551 41. Zhang, H., et al., *Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for*
- 552 solid cancers. Mol Cancer, 2023. 22(1): p. 58.

- 553 42. Jiang, M., et al., Alterations of DNA damage response pathway: Biomarker and therapeutic strategy
- 554 for cancer immunotherapy. Acta Pharm Sin B, 2021. 11(10): p. 2983-2994.
- 43. Ward, A.B., et al., Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
- 556 MedComm (2020), 2020. 1(2): p. 121-128.
- 557 44. Li, X., et al., Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
- 558 Nature Reviews Clinical Oncology, 2019. 16(7): p. 425-441.
- 559 45. Ma, W., B. Pham, and T. Li, *Cancer neoantigens as potential targets for immunotherapy.* Clin Exp
- 560 Metastasis, 2022. **39**(1): p. 51-60.
- 561 46. Johnson, B.J., et al., Single-cell perforin and granzyme expression reveals the anatomical localization
- 562 of effector CD8+ T cells in influenza virus-infected mice. Proceedings of the National Academy of
- 563 Sciences, 2003. 100(5): p. 2657-2662.
- 564 47. Peng, D., et al., *Epigenetic silencing of TH1-type chemokines shapes tumour immunity and* 565 *immunotherapy*. Nature, 2015. **527**(7577): p. 249-53.
- 566 48. Reschke, R. and T.F. Gajewski, CXCL9 and CXCL10 bring the heat to tumors. Science immunology,
- 567 2022. **7**(73): p. eabq6509.
- 49. Li, Y., et al., *CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy:* 569 *A Pan-Cancer Analysis.* Front Immunol, 2022. 13: p. 951247.
- 570 50. Hsieh, C.H., et al., Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor
- 571 *Treatment in Cancer.* Cancers (Basel), 2022. 14(2).
- 572 51. Tannir, N.M., et al., Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine
- 573 kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of
- 574 cohorts A, G, H and I of IVY Phase I study. Int J Cancer, 2021. 149(2): p. 403-408.
- 575 52. Mortezaee, K. and J. Majidpoor, *Checkpoint inhibitor/interleukin-based combination therapy of cancer.*

- 576 Cancer Med, 2022. **11**(15): p. 2934-2943.
- 577 53. Briukhovetska, D., et al., Interleukins in cancer: from biology to therapy. Nat Rev Cancer, 2021. 21(8):

578 p. 481-499.

- 579 54. Long, J., et al., Identification of NOTCH4 mutation as a response biomarker for immune checkpoint
- 580 *inhibitor therapy.* BMC Med, 2021. **19**(1): p. 154.
- 581 55. Dong, Y., et al., *PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint*
- 582 *inhibitors in skin cutaneous melanoma and non-small cell lung cancer.* Cell Prolif, 2022: p. e13283.

583